PRFZ - PowerShares FTSE RAFI US 1500 Sm-Mid ETF

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
+1.69 (+1.26%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close133.78
Bid134.41 x 300
Ask136.38 x 300
Day's Range133.82 - 135.49
52 Week Range112.11 - 135.81
Avg. Volume38,696
Net Assets1.84B
PE Ratio (TTM)N/A
YTD Return13.81%
Beta (3y)1.03
Expense Ratio (net)0.39%
Inception Date2006-09-20
Trade prices are not sourced from all markets
  • What Are Insys Therapeutics’ Top Priorities?
    Market Realist6 days ago

    What Are Insys Therapeutics’ Top Priorities?

    Insys (INSY) is taking strategic steps to restore stakeholder confidence. The company aims to achieve one NDA (or new drug application) per year over the next five years. Insys is targeting treatments for orphan diseases, neurological diseases like pediatric epilepsy, genetic conditions like Prader-Willi syndrome, and treatments for secondary allergic reactions, anorexia, and products for opioid overdose.

  • Morningstar9 months ago

    Contrarian Rebalancing Gives This Earnings-Focused ETF an Edge

    WisdomTree MidCap Earnings' rebalancing approach should keep its valuation in check.

  • Zacks10 months ago

    Top-Ranked ETFs That Crushed S&P 500 in the Bull Market

    We have presented a bunch of top performing ETFs of the Bull Market that will continue to outperform in the coming months.